Please assess the completion status of the following clinical trial:

Trial Title: Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 8 - 30,~* duration of diabetes 4 - 12 months,~* weight greater than 27.5 kg,~* stimulated C-peptide \>= 0.2 pmol/ml~Exclusion Criteria:~* asthma,~* history of hepatitis C, hepatitis B, HIV

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2 over a 14 day treatment period.
- 2 (Type: PLACEBO_COMPARATOR): Normal saline infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).